Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information

Stock Information for Pernix Therapeutics Holdings Inc - Ordinary Shares

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Pernix Therapeutics Holdings Inc - Ordinary Shares

Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets
Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2025 Financial Results on February 14, 2025
Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R)
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets
Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.